Zürich – October 15th 2011
The United States Patent and Trademark Office (USPTO) has granted a US Patent (12/450,204) to CovalX AG for a new method to characterize the effect of potential drugs on protein-protein interaction. The patent is based on the used of CovalX’s proprietary technology.
The method of the invention is adapted to high through put analysis and is based on a specially developed cross-linking chemistry and ultra high mass MALDI mass spectrometry. This new method allows a fast and direct analysis of potential therapeutic targeting protein-protein interactions. The method can be applied in most formulation.
